- Treatment of Renally Impaired Patients With Venous Thromboembolism: Awaiting the VERDICTFebruary 13, 2019 | March-April 2019, Volume 16, Issue 2
Dr. Linkins discusses the VERDICT Trial which compares reduced doses of apixaban and rivaroxaban with standard-of-care in adult patients with symptomatic proximal deep vein thrombosis or pulmonary embolism and moderate or severe renal insufficiency.
- Rivaroxaban Clinical Trials in 2018: Successes, Failures, and Lessons LearnedDecember 21, 2018 | January-February 2019, Volume 16, Issue 1
Dr. Linkins discusses the successes, failures, and lessons from rivaroxaban clinical trials that took place in 2018.
- Prevention of Central Venous Catheter-Related Thrombosis: Reality or Still a Dream?October 10, 2018 | November-December 2018, Volume 15, Issue 6
Dr. Linkins discusses low-molecular weight heparin and direct oral anticoagulants for the prevention of central venous catheter-related thrombosis.
- Venous Thrombosis on One Side and Bleeding on the Other: How to Walk the Fence in Cancer Patients With Thrombosis and ThrombocytopeniaAugust 15, 2018 | September-October 2018, Volume 15, Issue 5
Dr. Linkins provides guidance on how to manage recurrent thrombosis and bleeding in a cancer patient with severe thrombocytopenia that develops VTE.
- Ground-Breaking Trial Shows Aspirin Is As Effective As Rivaroxaban Following Hip and Knee ArthroplastyJune 19, 2018 | July-August 2018, Volume 15, Issue 4
Dr. Linkins looks at evidence that demonstrates that aspirin is as effective as oral anticoagulant rivaroxaban post hip and knee arthroplasty in a significant subset of patients.
- Therapeutic Instead of Prophylactic Platelet Transfusions for Autologous Stem Cell Transplant Patients: Ready for Prime Time?April 03, 2018 | May-June 2018, Volume 15, Issue 3
Dr. Linkins reviews revised clinical practice guidelines for platelet transfusions in patients with cancer, focusing on patients undergoing AHSCT as an exemption to the general rule to provide prophylactic platelet transfusions to those undergoing cancer treatment.
- Physicians Beware: Direct Oral Anticoagulants Do Interact With Some Commonly Used DrugsFebruary 05, 2018 | March-April 2018, Volume 15, Issue 2
Dr. Linkins discusses data on the potential for interaction between DOACs and selected drugs but warns that results should be interpreted with caution.
- A Pill Instead of a Needle for Cancer-Associated Venous Thromboembolism? YES!January 10, 2018 | January-February 2018, Volume 15, Issue 1
Dr. Linkins considers oral direct anticoagulants as an attractive alternative to low-molecular-weight heparin injections to treat patients with cancer-associated VTE.
- What Is Old Is New Again in the Treatment of Severe Refractory Heparin-Induced ThrombocytopeniaOctober 10, 2017 | November-December 2017, Volume 14, Issue 6
Dr. Linkins reviews the use of IVIg for off-label treatment of severe heparin-induced thrombocytopenia that has proven refractory to standard measures.
- Tranexamic Acid: Another Tool for Treatment of Postpartum HemorrhageAugust 14, 2017 | September-October 2017, Volume 14, Issue 5
Dr. Linkins reviews the WOMAN study, which demonstrates the usefulness of tranexamic acid to reduce maternal mortality due to postpartum hemorrhage.